Methods and compositions for treating infections comprising a local anesthetic
The present invention is directed to a drug depot useful for reducing, preventing or treating an infection in a patient in need of such treatment. The drug depot includes a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof. The drug depot is administered at a site to reduce, prevent or treat an infection. The drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at the site and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days at the site.
1. A method of treating or preventing an infection in a patient in need of such treatment, the method comprising administering one or more biodegradable drug depots comprising a polymer and a therapeutically effective amount of a local anesthetic comprising bupivacaine or pharmaceutically acceptable salt thereof, the drug depot being administered at a site to reduce, prevent or treat an infection, wherein the drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at the site from a layer, wherein between 15 and 25% of the bupivacaine is released within a 24 hour period and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days at the site, wherein the polymer comprises a particle size of about 10 μm to about 40 μm and is capable of degrading in less than 30 days after the drug depot is administered at the site.
2. A method of treating or preventing an infection according to claim 1 , wherein the drug depot is capable of releasing between 50 and 800 mg/day of the local anesthetic or pharmaceutically acceptable salt thereof for a period of 4 to 10 days.
3. A method of treating or preventing an infection according to claim 1 , wherein the drug depot comprises a polymer comprising one or more of poly(lactide-co-glycolide), polylactide, polyglycolide, polyorthoester, D-lactide, D,L-lactide, poly(D,L-lactide), L-lactide, poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-glycolide-co-caprolactone), polycaprolactone or a combination thereof.